Evidence map›Paper›PMID 26986115›Full record

Observational studyMedicine2016

Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis.

Kang Wang, Wei Xing Guo, Min Shan Chen, Yi Lei Mao, Bei Cheng Sun, Jie Shi, Yao Jun Zhang, Yan Meng, Ye Fa Yang, Wen Ming Cong and 3 more

Open access · goldAbstract readComparative StudyMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 7 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 7 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Kang WangFrom the Department of Hepatic Surgery (KW, WXG, JS, MCW, WYL, SQC), Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai; Faculty of Medicine (WYL), The Chinese University of Hong Kong, Shatin, Hong Kong SAR; Department of Hepatobiliary Surgery (MSC, YJZ), SunYat-sen University Cancer Center; Department of Liver Surgery (YLM), Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and PUMC, Beijing; Liver Transplantation Center of the First Affiliated Hospital (BCS), Nanjing Medical University, Nanjing, Jiangsu Province; Department of Radiotherapy (YM); Department of Invasive Technology (YFY); and Department of Pathology (WMC), Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China.
Wei Xing Guo
Min Shan Chen
Yi Lei Mao
Bei Cheng Sun
Jie Shi
Yao Jun Zhang
Yan Meng
Ye Fa Yang
Wen Ming Cong
Meng Chao Wu
Wan Yee Lau
Shu Qun Cheng
Science and Technology Department of Sichuan Province · CNChinese University of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The optimal treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) remains controversial. We aimed to investigate the best treatment for patients with HCC with PVTT. From January 2002 to January 2014, the data from all consecutive patients with HCC with PVTT who underwent surgical treatment (ST),TACE,TACE combined with sorafenib (TACE-Sor), or TACE combined with radiotherapy (TACE-RT) in the 4 largest tertiary hospitals in China were analyzed retrospectively. The patients were divided into 3 subtypes according to the extent of PVTT in the portal vein (type I-III). The primary endpoint was overall survival (OS). A total of 1580 patients with HCC with PVTT were included in the study. The median survival times (MST) for ST (n = 745) for type I, II, and III patients (95% CI) were 15.9 (13.3-18.5), 12.5 (10.7-14.3), and 6.0 (4.3-7.7) months, respectively. The corresponding figures for patients after TACE (n = 604) were 9.3 (5.6-12.9), 4.9 (4.1-5.7), and 4.0 (3.1-4.9), respectively; for patients after TACE-Sor (n = 113) 12.0 (6.6-17.4), 8.9 (6.7-11.1), and 7.0 (3.0-10.9), respectively; and for patients after TACE-RT (n = 118) 12.2 (0-24.7), 10.6 (6.8-14.5), and 8.9 (5.2-12.6), respectively. Comparison among the different treatments for the 3 subtypes of PVTT patients after propensity score (PS) matching showed the effectiveness of ST to be the best for type I and type II PVTT patients, and TACE-RT was most beneficial for type III patients. Treatment was an independent risk factor of OS. ST was the best treatment for type I and II PVTT patients with Child-Pugh A and selected B liver function. TACE-RT should be given to type III PVTT patients.

Indexed as

Chemoembolization, TherapeuticAntineoplastic AgentsCarcinoma, HepatocellularChinaCombined Modality TherapyFemaleHumansLiver NeoplasmsMaleMiddle AgedNiacinamidePhenylurea CompoundsPortal VeinPropensity ScoreRadiotherapyRetrospective StudiesAntineoplastic AgentsNiacinamidePhenylurea CompoundsSorafenib

Identifiers

PMID26986115
PMCPMC4839896
OpenAlexW2336744821

What OpenQuestion holds

Textmetadata
LicenceCC BY-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.